Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Daniel J. Sisler"'
Autor:
Daniel J. Sisler, Trista K. Hinz, Anh T. Le, Emily K. Kleczko, Raphael A. Nemenoff, Lynn E. Heasley
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionThe KRAS(G12C) mutation is the most common genetic mutation in North American lung adenocarcinoma patients. Recently, direct inhibitors of the KRASG12C protein have been developed and demonstrate clinical response rates of 37-43%. Importa
Externí odkaz:
https://doaj.org/article/cb227c2f9f5440f7a6ba0d3df80f32ec
Autor:
Daniel J Sisler, Trista K Hinz, Anh T Le, Emily K Kleczko, Raphael A Nemenoff, Lynn E Heasley
The KRAS(G12C) mutation is the most common genetic mutation in North American lung adenocarcinoma patients. Recently, direct inhibitors of the KRASG12C protein have been developed and demonstrate clinical response rates of 37-43%. Importantly, these
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bde11dd6433898d1c6439b0f1b7e3c60
https://doi.org/10.1101/2022.08.19.504555
https://doi.org/10.1101/2022.08.19.504555
Autor:
Lynn E. Heasley, Daniel J Sisler
Publikováno v:
Future Medicinal Chemistry. 11:1083-1086
Autor:
Trista K. Hinz, Colin Sempeck, Lindsay Marek, Bonnie L. Bullock, Howard Li, Daniel J Sisler, Natalia Gurule, Molishree Joshi, Raphael A. Nemenoff, Sean Korpela, Lynn E. Heasley
Publikováno v:
Molecular Cancer Research. 18:B51-B51
Mutations in the KRAS oncogene are frequent in lung adenocarcinomas (LUADs). Unfortunately, KRAS lacks a pharmacologically available inhibitor for precision oncology. Immunotherapies have recently become available and are now FDA approved for LUAD, a